EMAIL THIS PAGE TO A FRIEND

Molecular cancer therapeutics

CDKN2A/p16 Loss Implicates CDK4 as a Therapeutic Target in Imatinib-Resistant Dermatofibrosarcoma Protuberans.


PMID 25852058

Abstract

Dermatofibrosarcoma protuberans (DFSP) is an aggressive PDGFB-dependent cutaneous sarcoma characterized by infiltrative growth and frequent local recurrences. Some DFSP progress to a higher-grade fibrosarcomatous form, with rapid growth and increased risk of metastasis. Imatinib provides clinical benefit in approximately 50% of patients with unresectable or metastatic DFSP. However, efficacious medical therapies have not been developed for imatinib-resistant DFSP. We established a model of imatinib-resistant DFSP and evaluated CDK4/6 inhibition as a genomically credentialed targeted therapy. DFSP105, an imatinib-resistant human cell line, was established from a fibrosarcomatous DFSP (FS-DFSP), and was studied by SNP arrays and sequencing to identify targetable genomic alterations. Findings were validated in vitro and in vivo, and confirmed in a series including 12 DFSP and 6 FS-DFSP. SNP analysis of DFSP105 revealed a homozygous deletion encompassing CDKN2A and CDKN2B. The resultant p16 loss implicated CDK4/6 as a potential therapeutic target in DFSP. We further demonstrated CDKN2A homozygous deletion in 1 of 12 conventional DFSP and 2 of 6 FS-DFSP, whereas p16 expression was lost in 4 of 18 DFSP. In vitro treatment of DFSP105 with two structurally distinct selective CDK4/6 inhibitors, PD-0332991 and LEE011, led to inhibition of RB1 phosphorylation and inhibition of proliferation (GI50 160 nmol/L and 276 nmol/L, respectively). In vivo treatment of DFSP105 with PD-0332991 (150 mg/kg) inhibited xenograft growth in mice, in comparison with imatinib-treated or -untreated tumors. In conclusion, CDKN2A deletion can contribute to DFSP progression. CDK4/6 inhibition is a preclinically effective treatment against p16-negative, imatinib-resistant FS-DFSP, and should be evaluated as a therapeutic strategy in patients with unresectable or metastatic imatinib-resistant DFSP.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

GW10811F Anti-CD34 antibody produced in chicken, affinity isolated antibody, buffered aqueous solution
SAB4300690
Anti-CD34 antibody produced in rabbit, affinity isolated antibody
GW21185 Anti-CDKN2A antibody produced in chicken, affinity isolated antibody, buffered aqueous solution
SAB2502016
Anti-Cdkn2a antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB2501929
Anti-CDKN2A antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB2900054
Anti-EPHA4 (AB1) antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB2900055
Anti-EPHA4 (AB2) antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
E6900 Anti-EphA4 antibody produced in goat, affinity isolated antibody, lyophilized powder
SAB2107644
Anti-EPHA4 antibody produced in rabbit, affinity isolated antibody
SAB1306566
ANTI-P16INK4A (C-TERM E119) antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB4300387
Anti-RB1 (Ab-780) antibody produced in rabbit, affinity isolated antibody
SAB4300385
Anti-RB1 (Ab-795) antibody produced in rabbit, affinity isolated antibody
SAB4300386
Anti-RB1 (Ab-807) antibody produced in rabbit, affinity isolated antibody
AV33212
Anti-RB1 antibody produced in rabbit, affinity isolated antibody
HPA006628
Anti-RBM14 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
AV40635
Anti-RBM14 antibody produced in rabbit, affinity isolated antibody
AV37269
Anti-RBM14 antibody produced in rabbit, IgG fraction of antiserum
WH0000947M1
Monoclonal Anti-CD34 antibody produced in mouse, clone 5F3, purified immunoglobulin, buffered aqueous solution
SAB1403649
Monoclonal Anti-CD34 antibody produced in mouse, clone 5A6, purified immunoglobulin, buffered aqueous solution
SAB4700160 Monoclonal Anti-CD34 antibody produced in mouse, clone 4H11[APG], purified immunoglobulin, buffered aqueous solution
SAB4700736 Monoclonal Anti-CD34 antibody produced in mouse, clone 581, purified immunoglobulin, buffered aqueous solution
SAB5300498
Monoclonal Anti-CDKN2A antibody produced in mouse, clone 1E12E10, ascites fluid
SAB5300499
Monoclonal Anti-CDKN2A antibody produced in mouse, clone 5A8A4, ascites fluid
WH0002043M2
Monoclonal Anti-EPHA4 antibody produced in mouse, clone 6H7, purified immunoglobulin, buffered aqueous solution
SAB5300482 Monoclonal Anti-EPHA4 antibody produced in mouse, clone 7D3D4, ascites fluid
SAB5300483 Monoclonal Anti-EPHA4 antibody produced in mouse, clone 6C1B6, ascites fluid
SAB1403778
Monoclonal Anti-EPHA4, (C-terminal) antibody produced in mouse, clone 5A9, purified immunoglobulin, buffered aqueous solution
SAB5300213 Monoclonal Anti-RB1 antibody produced in mouse, clone 7E4B8, ascites fluid
SAB1404825
Monoclonal Anti-RBM14 antibody produced in mouse, clone 4E1, ascites fluid
PLA0178
Rabbit anti-p16INK4a Antibody, Affinity Purified, Powered by Bethyl Laboratories, Inc.